Recent News & Events

350,000 units of Tolcylen™ products dispensed, 5th Patent issued...

September 27, 2019

Approximately 350,000 units of Tolcylen™ products have now been dispensed by over 2,200 physicians and clinics helping Tolcylen™ become the fastest growing product line in its category.  Marlinz Pharma has received notice of allowance for it's 5th patent covering the Tolcylen™ product line.

Tolcylen™ approved for Phase 1 Drug Study...

August 28, 2019 

Tolcylen™ has been approved for a multi-site, double-blinded, placebo-controlled drug study.  The study is currently in the enrollment phase.  This FDA registered study will measure mycological and clinical outcomes for intended and off-label uses.  It will include approximately 120 patients from 6 clinical sites throughout the United States.

Marlinz Pharma announces 185,000 units Tolcylen™ sold...

August 9, 2018

Marlinz Pharma has announced that they have reached a milestone of over 1300 physicians dispensing Tolcylen™ to their patients with over 185,000 units sold to date.  Marlinz Pharma has been granted 2 patents covering the unique combination Tolcylen product lines. 

Meetings / Conferences

Texas Dermatological Spring Meeting
ACFAS Annual Scientific Conference
APMA National
IFAF Las Vegas Seminar - TENTATIVE